R&D

Make that 2 prospective blockbuster approvals in 1 day for Novartis as FDA OKs targeted cancer therapy

Cell/Gene Tx, R&D

UPDATED: Novartis rolls out its next big drug at a record-setting price of $2.12M — let the gene therapy pricing debate begin

People, Pharma

UPDATED: Project Snow White: Internal probe reveals former MiMedx C-suite spied on employees, lied to regulators and misled investors
More news caret

calendar Protocols

Quick hits from around the biopharma web

May 24

Life sciences fund raises €118M for its next round of bets; Gilead scraps Alpine alliance

May 23

Santhera enters license agreement with Chiesi Group; Tonix's cocaine intoxication drug, Iovance's cervical cancer treatment win FDA's breakthrough status

May 22

Array shares surge as PhIII sets the stage for FDA filing; FDA gives Avadel priority review

May 21

Top AstraZeneca I/O exec jumps to Seattle Genetics as first CCO; Woodford fund downgraded as woes mount

More Protocols caret

person Peer Review

Weekly biopharma careers news report

May 24

Akrevia scoops ex-Arsanis chief René Russo as CEO; Scott Gottlieb jumps back into industry; Seattle Genetics raids AstraZeneca for CCO

May 17

Biogen exec Paul McKenzie heads to CSL as COO; Pulmatrix CEO resigns

May 10

Bicycle signs on new clinical execs in pipeline drive; Howard Stern signs on as FogPharma CSO

May 3

Peer Review: Anil Singhal assumes leadership of Adicet Bio; Adaptive Biotech woos Genentech vet as CMO

More peer review caret

Dollar Premium

Biopharma BD teams are speeding into the fast lane — cash in hand — as dealmaking continues to heat up in Q1 offensive

The top 50 biotechs by market cap — and what their CEOs’ compensation deals tell us about biopharma

The BCMA frenzy: Tracking the 37 drugs around the world racing to overtake bluebird bio and Celgene

Top 5 Chinese players: What does Everest's landmark deal with Immunomedics say about the flurry of in-licensing to China?

Going gangbusters: The top 20 biotech platform deals by upfront cash

Another player in the gene therapy field is gunning for the Duchenne MD crown — and here’s what they're betting on

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major league stinkers

Top 20 cancer drug deals: AstraZeneca just changed the global landscape for dealmaking in oncology

The top 10 Alzheimer's deals tell us a lot about a big change of direction for a disaster-prone field

bullhorn Bioregnum

The view from John Carroll

May 14

Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs

May 10

That feeling you get when you hit the finish line, and then set new goals

Apr 17

Ned Sharpless is not playing with the FDA’s gold standard — any more than Scott Gottlieb did

Apr 15

SCOTUS just turned its back on Allergan’s legal maneuver to take a blow at inter partes review. What did you expect?

More opinion caret

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back